ASCO GUIDELINES Bundle

Chronic Cancer Pain

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/770601

Contents of this Issue

Navigation

Page 4 of 13

5 Risk Assessment, Mitigation, and Universal Precautions With Opioid Use ➤ Clinicians should assess the potential risks and benefits when initiating treatment that will incorporate long-term use of opioids. (Moderate Recommendation; IC-B-I) ➤ Clinicians should clearly understand terminology such as tolerance, dependence, abuse, and addiction as it relates to the use of opioids for pain control. (Moderate Recommendation; IC-B-I) ➤ Clinicians should incorporate a universal precautions approach to minimize abuse, addiction, and adverse consequences of opioid use such as opioid-related deaths. Clinicians should be cautious in co- prescribing other centrally acting drugs, particularly benzodiazepines (Table 5). (Moderate Recommendation; EB/IC-B-I) ➤ Clinicians should understand pertinent laws and regulations regarding the prescribing of controlled substances. (Moderate Recommendation; IC-B-I) ➤ Clinicians should educate patients and family members regarding the risks and benefits of long-term opioid therapy and the safe storage, use, and disposal of controlled substances. (Moderate Recommendation; IC-B-I) • Clinicians are encouraged to address possible myths and misconceptions about medication use and should educate patients about the need to be cautious when using alcohol or sedating over-the-counter medications or in receiving centrally acting medications from other physicians. Qualifying statement. Education and information about treatment should ideally take into account the patient's literacy level and the need for interpreters and should be provided in a culturally congruent manner. ➤ If opioids are no longer warranted, clinicians should taper the dose to avoid abstinence syndrome. The rate of tapering and the use of co- therapies to reduce adverse effects should be individualized for each patient. (Moderate Recommendation; EB/IC-B-I)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Chronic Cancer Pain